ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 399,04
-0,53%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Actualités

ALNY Alnylam Pharmaceuticals Inc

143,31
-0,40 (-0,28%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Alnylam Pharmaceuticals Inc ALNY NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,40 -0,28% 143,31 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
144,08 143,00 146,065 143,31 143,71
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/4/202414:00BWAlnylam to Webcast Conference Call Discussing First Quarter..
07/4/202414:00BWAlnylam Presents Positive Results from the KARDIA-2 Phase 2..
20/3/202413:00BWAlnylam to Webcast Investor Event to Discuss Results from..
13/3/202412:30BWAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis..
06/3/202412:50BWAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse,..
05/3/202423:39BWAlnylam annonce des résultats positifs de l’étude KARDIA-2..
05/3/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202413:30BWAlnylam Reports Positive KARDIA-2 Topline Study Results..
04/3/202422:33EDGAR2Form 8-K - Current report
29/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:00EDGAR2Form 144 - Report of proposed sale of securities
27/2/202414:30BWAlnylam to Webcast Presentations at Upcoming March Investor..
20/2/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202422:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202414:10EDGAR2Form 8-K - Current report
15/2/202414:00BWAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year..
10/2/202400:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202414:00BWAlnylam to Webcast Conference Call Discussing Fourth Quarter..
19/1/202422:31EDGAR2Form 8-K - Current report
09/1/202414:05BWAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year..
08/1/202413:00EDGAR2Form 8-K - Current report
08/1/202400:00BWAlnylam Announces Preliminary* Fourth Quarter and Full Year..
02/1/202413:30BWAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan..
29/12/202322:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202322:03EDGAR2Form 144 - Report of proposed sale of securities
13/12/202313:30BWAlnylam Highlights Significant Progress with Platform..
11/12/202322:07EDGAR2Form 144 - Report of proposed sale of securities
06/12/202314:00BWAlnylam to Webcast Virtual R&D Day
30/11/202314:00BWAlnylam Ranks #1 on Boston Globe’s Top Places to Work List..
12/11/202318:08BWAlnylam präsentiert positive Ergebnisse der..
11/11/202322:00BWAlnylam Presents Positive Results from the KARDIA-1 Phase 2..
07/11/202314:00BWAlnylam to Webcast Presentations at Upcoming November..
02/11/202313:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202313:10EDGAR2Form 8-K - Current report
02/11/202313:00BWAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial..
26/10/202320:00BWAlnylam Recognized by Science Magazine as Top Employer for..
25/10/202323:19BWAlnylam Announces Publication of Results from APOLLO-B Phase..
25/10/202317:05BWAlnylam Reports Additional Positive Interim Phase 1 Results..
19/10/202314:00BWAlnylam to Webcast Conference Call Discussing Third Quarter..
10/10/202313:30EDGAR2Form 8-K - Current report
10/10/202313:02IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations

Dernières Valeurs Consultées

NASDAQ
ALNY
Alnylam Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés